Abstract
Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization – however, abrogating NI formation following stent implantation has been hampered by an incomplete understanding of the pathogenesis of in-stent lesions. While numerous mechanisms have been proposed to explain the pathogenesis of ISR, data from human and animal models have yielded conflicting results. Herein, we review key studies of NI development following vascular injury with a focus on the origin of cells participating in NI formation.
Keywords: In-stent restenosis, neointima, smooth muscle cell, endothelial cell, vascular progenitor cell, endothelial progenitor cell, drug-eluting stents, hyperplasia, contractile phenotype
Cardiovascular & Hematological Disorders-Drug Targets
Title: Pathogenesis of Neointima Formation Following Vascular Injury
Volume: 11 Issue: 1
Author(s): Ali Pourdjabbar, Benjamin Hibbert, Trevor Simard and Xiaoli Ma
Affiliation:
Keywords: In-stent restenosis, neointima, smooth muscle cell, endothelial cell, vascular progenitor cell, endothelial progenitor cell, drug-eluting stents, hyperplasia, contractile phenotype
Abstract: Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization – however, abrogating NI formation following stent implantation has been hampered by an incomplete understanding of the pathogenesis of in-stent lesions. While numerous mechanisms have been proposed to explain the pathogenesis of ISR, data from human and animal models have yielded conflicting results. Herein, we review key studies of NI development following vascular injury with a focus on the origin of cells participating in NI formation.
Export Options
About this article
Cite this article as:
Pourdjabbar Ali, Hibbert Benjamin, Simard Trevor and Ma Xiaoli, Pathogenesis of Neointima Formation Following Vascular Injury, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152911795945169
DOI https://dx.doi.org/10.2174/187152911795945169 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Current Alzheimer Research Coronary Artery Aneurysms as a Cause of Acute Coronary Syndrome Presentation - A Focused Review
Current Cardiology Reviews Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry Antithrombotic Therapy After TAVR
Current Vascular Pharmacology Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Inhibition of Platelet Adhesion to Collagen as a New Target for Antithrombotic Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders Gender, Hormones and the Transmissible Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Protein disulfide isomerase and Nox: new partners in redox signaling
Current Pharmaceutical Design Pharmacokinetics and Tissue Distribution of Fargesin After Oral Administration in Rats by High Performance Liquid Chromatography
Current Pharmaceutical Analysis Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Omega-3 Fatty Acids and the Expression of Membrane Proteins: Emphasis on Molecules of Immunologic Importance.
Current Organic Chemistry Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology Congestive Heart Failure and Thyroid Dysfunction: The Role of the Low T3 Syndrome and Therapeutic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine